CTLA4 and cancer: Interestingly, our network-based analysis recognized the interactions between IFNG and the effector PTPs activated by PD-1 and CTLA4 signaling as a potential hub through which the effects of ICI cancer treatment could lead to the observed differences between irMyositis and DM38.